Updated: ImprimisRx's Approval And Superiority Claims For Compounded Drug Draw FDA Warning
The company known for compounding versions of Martin Shkreli’s Daraprim and Allergan’s Restasis is hit with a warning letter for promotions in professional periodicals about its compounded eye drop.
You may also be interested in...
Allergan proudly describes itself as a 'bold' company, and its latest move to protect its Restasis franchise certainly qualifies as a reason why. But Allergan’s unlikely position as the industry’s self-appointed leader in social responsibility should make the rest of the industry cringe.
Martin Shkreli says he will not lower price of antiparasitic Daraprim, noting shareholders want firm to make as much money as possible; he thanks Express Scripts’ CMO for not excluding the drug.
Hemp industry and private attorneys glad Birenbaum, who was the chief cannabis policy advisor to governors of New York and Rhode Island, given prominent role at FDA that could spur regulatory action.